UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 42

Sortiert nach

Inhibitors in AKTion: ATP-competitive vs allosteric

Biochemical Society transactions, 2020-06, Vol.48 (3), p.933-943

2020

Volltextzugriff (PDF)

The phosphatidylinositol 3-Kinase-AKT pathway in human cancer

Nature reviews. Cancer, 2002-07, Vol.2 (7), p.489-501

2002

Volltextzugriff (PDF)

Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients

PLoS computational biology, 2018-01, Vol.14 (1), p.e1005924

2018

Volltextzugriff (PDF)

Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies

Nature genetics, 2010-01, Vol.42 (1), p.77-82

2010

Volltextzugriff (PDF)

Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death

Molecular systems biology, 2012, Vol.8 (1), p.589-n/a

2012

Volltextzugriff (PDF)

Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma

Proceedings of the National Academy of Sciences - PNAS, 2007-12, Vol.104 (50), p.20007-20012

2007

Volltextzugriff (PDF)

tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers

Proceedings of the National Academy of Sciences - PNAS, 2009-06, Vol.106 (23), p.9435-9440

2009

Volltextzugriff (PDF)

Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development

Cancer research (Chicago, Ill.), 2007-07, Vol.67 (13), p.6083-6091

2007

Volltextzugriff (PDF)

A kinase-independent function of AKT promotes cancer cell survival

eLife, 2014-12, Vol.3

2014

Volltextzugriff (PDF)

Identification of the JNK Signaling Pathway as a Functional Target of the Tumor Suppressor PTEN

Cancer cell, 2007-06, Vol.11 (6), p.555-569

2007

Volltextzugriff (PDF)

EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer

Nature communications, 2017-12, Vol.8 (1), p.2035-12, Article 2035

2017

Volltextzugriff (PDF)

Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells

Cancer research (Chicago, Ill.), 2006-08, Vol.66 (16), p.7864-7869

2006

Volltextzugriff (PDF)

phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation

Proceedings of the National Academy of Sciences - PNAS, 2010-04, Vol.107 (14), p.6459-6464

2010

Volltextzugriff (PDF)

IQGAP1 controls tight junction formation through differential regulation of claudin recruitment

Journal of cell science, 2015-03, Vol.128 (5), p.853-862

2015

Volltextzugriff (PDF)

STEAP: A Prostate-Specific Cell-Surface Antigen Highly Expressed in Human Prostate Tumors

Proceedings of the National Academy of Sciences - PNAS, 1999-12, Vol.96 (25), p.14523-14528

1999

Volltextzugriff (PDF)

Targeting un-MET needs in advanced non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2022-02, Vol.164, p.56-68

2022

Volltextzugriff (PDF)

Identification of an Androgen-Dependent Enhancer within the Prostate Stem Cell Antigen Gene

Molecular endocrinology (Baltimore, Md.), 2002-10, Vol.16 (10), p.2323-2337

2002

Volltextzugriff (PDF)

Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer

The Journal of clinical investigation, 2009-10, Vol.119 (10), p.3000-3010

2009

Volltextzugriff (PDF)

Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine

Pharmacogenomics and personalized medicine, 2021-01, Vol.14, p.1517-1535

2021

Volltextzugriff (PDF)

HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability

Cancer cell, 2004-11, Vol.6 (5), p.517-527

2004

Volltextzugriff (PDF)

A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity

British journal of cancer, 2020-08, Vol.123 (4), p.542-555

2020

Volltextzugriff (PDF)

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma

The Journal of clinical investigation, 2020-11, Vol.130 (11), p.5875-5892

2020

Volltextzugriff (PDF)

Epidermal growth factor receptor inhibitors in oncology

Current opinion in oncology, 2010-11, Vol.22 (6), p.573-578

2010

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(41)
Dissertationen
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(31)
Humans
(27)
Life Sciences & Biomedicine
(26)
Animals
(15)
Oncology
(14)
Cell Line, Tumor
(13)
Cancer
(12)
Mice
(11)
Mutation
(11)
Tumors
(9)
Male
(8)
Protein Kinase Inhibitors - Pharmacology
(8)
Proteins
(8)
Kinases
(7)
Phosphorylation
(7)
Science & Technology - Other Topics
(6)
Signal Transduction
(6)
Biological And Medical Sciences
(5)
Drug Resistance
(5)
Gene Expression Regulation, Neoplastic
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Inhibitors in AKTion: ATP-competitive vs allosteric

The phosphatidylinositol 3-Kinase-AKT pathway in human cancer

Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients

Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies

Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death

Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma

Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors

tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers

Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development

A kinase-independent function of AKT promotes cancer cell survival

Identification of the JNK Signaling Pathway as a Functional Target of the Tumor Suppressor PTEN

EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer

Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells

phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation

IQGAP1 controls tight junction formation through differential regulation of claudin recruitment

STEAP: A Prostate-Specific Cell-Surface Antigen Highly Expressed in Human Prostate Tumors

Targeting un-MET needs in advanced non-small cell lung cancer

Identification of an Androgen-Dependent Enhancer within the Prostate Stem Cell Antigen Gene

Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer

Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine

HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability

A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma

EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers

Epidermal growth factor receptor inhibitors in oncology

Suchergebnisse filtern